Browsing tag:

canagliflozin


On January 16, 2015 the Journal of Diabetes and its Complications shared positive findings from a recent post hoc analysis of Canagliflozin. Comprehensive data was analyzed from Phase 3 studies of Canagliflozin in adult patients with type 2 diabetes. This placebo-controlled study was comprised of four 26 week periods, with changes in HbA1c being sought[…]

Read More

The recent announcement from actor Tom Hanks revealing his diagnosis of Type 2 diabetes was stunning for Hollywood and his numerous fans. How could Tom, an in shape and active actor have this dreadful diagnosis? Endocrinologists believe a variety of factors contributed to Tom Hanks diabetes – particularly his type 2 status, including likely genetic components, weight[…]

Read More

Canagliflozin FDA approved as a new and unique treatment for type 2 diabetes. There were nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed positive results with greater glycemic control in patients. The recommended use for Canagliflozin patients includes a strict regimen of diet and exercise. The drug also outperforms similar[…]

Read More

An FDA Advisory Committee recommended the approval of Canagliflozin, CAS# 842133-18-0, for the treatment of type 2 diabetes. The approval in January 2013 was an encouraging move for Johnson and Johnson, who will market Canagliflozin as the brand Invokana. As an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least[…]

Read More